Drug-Resistant Tuberculosis--Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs

University College London, Centre for Clinical Microbiology, Division of Infection and Immunity, London, UK.
The Journal of Infectious Diseases (Impact Factor: 6). 04/2012; 205 Suppl 2(suppl 2):S228-40. DOI: 10.1093/infdis/jir858
Source: PubMed


Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. Following the declaration and the promotion in 1995 of directly observed treatment short course (DOTS), a cost-effective strategy to contain the tuberculosis epidemic, nearly 7 million lives have been saved compared with the pre-DOTS era, high cure rates have been achieved in most countries worldwide, and the global incidence of tuberculosis has been in a slow decline since the early 2000s. However, the emergence and spread of multidrug-resistant (MDR) tuberculosis, extensively drug-resistant (XDR) tuberculosis, and more recently, totally drug-resistant tuberculosis pose a threat to global tuberculosis control. Multidrug-resistant tuberculosis is a man-made problem. Laboratory facilities for drug susceptibility testing are inadequate in most tuberculosis-endemic countries, especially in Africa; thus diagnosis is missed, routine surveillance is not implemented, and the actual numbers of global drug-resistant tuberculosis cases have yet to be estimated. This exposes an ominous situation and reveals an urgent need for commitment by national programs to health system improvement because the response to MDR tuberculosis requires strong health services in general. Multidrug-resistant tuberculosis and XDR tuberculosis greatly complicate patient management within resource-poor national tuberculosis programs, reducing treatment efficacy and increasing the cost of treatment to the extent that it could bankrupt healthcare financing in tuberculosis-endemic areas. Why, despite nearly 20 years of WHO-promoted activity and >12 years of MDR tuberculosis-specific activity, has the country response to the drug-resistant tuberculosis epidemic been so ineffectual? The current dilemmas, unanswered questions, operational issues, challenges, and priority needs for global drug resistance screening and surveillance, improved treatment regimens, and management of outcomes and prevention of DR tuberculosis are discussed.

Download full-text


Available from: Rifat Atun,
  • Source
    • "Infections caused by antimicrobial-resistant microorganisms are often associated with poor clinical outcomes, resulting in increased morbidity and mortality. Many factors contribute to the spread of drug-resistant infections, including weak health systems,1,2 failing public health control,3 population movements and international travel of people who may be infected or asymptomatically colonized by resistant strains,4 unregulated use of antibiotics in many parts of the world5 and inappropriate drug use in countries with tighter regulation.4,6 There are also biological factors, including spread of resistant strains and spread of mobile genetic elements, that can transfer resistance genes between strains, species and genera. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the level of research funding awarded to UK institutions specifically for antimicrobial resistance-related research and how closely the topics funded relate to the clinical and public health burden of resistance. Databases and web sites were systematically searched for information on how infectious disease research studies were funded for the period 1997-2010. Studies specifically related to antimicrobial resistance, including bacteriology, virology, mycology and parasitology research, were identified and categorized in terms of funding by pathogen and disease and by a research and development value chain describing the type of science. The overall dataset included 6165 studies receiving a total investment of £2.6 billion, of which £102 million was directed towards antimicrobial resistance research (5.5% of total studies, 3.9% of total spend). Of 337 resistance-related projects, 175 studies focused on bacteriology (40.2% of total resistance-related spending), 42 focused on antiviral resistance (17.2% of funding) and 51 focused on parasitology (27.4% of funding). Mean annual funding ranged from £1.9 million in 1997 to £22.1 million in 2009. Despite the fact that the emergence of antimicrobial resistance threatens our future ability to treat many infections, the proportion of the UK infection-research spend targeting this important area is small. There are encouraging signs of increased investment in this area, but it is important that this is sustained and targeted at areas of projected greatest burden. Two areas of particular concern requiring more investment are tuberculosis and multidrug-resistant Gram-negative bacteria.
    Journal of Antimicrobial Chemotherapy 02/2014; 69(2):548-554. DOI:10.1093/jac/dkt349 · 5.31 Impact Factor
  • Source
    • "In 2008, MDR-TB killed more than 150 000 people globally (WHO 2012a). Global surveillance has mainly been based on reports from surveys conducted previously while routine surveillance data are limited (Zignol et al. 2012a; Zumla et al. 2012). The emergence of extensively drug-resistant TB (XDR-TB) is causing even greater concern for future TB control strategies (Gandhi et al. 2010), especially in highly HIV-prevalent countries, where the prognosis of these patients varies significantly from very poor with 100% mortality (Cooke et al. 2011) to relatively better outcomes in other cases (Orenstein et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multidrug-resistant tuberculosis (MDR-TB) is posing a great threat to global TB control. The burden in Zambia is not well defined because routine surveillance data are scarce. We reviewed national MDR-TB data for the last decade to inform future public health policy with respect to MDR-TB in Zambia. Retrospective review of national surveillance of MDR-TB data, TB programme and laboratory reports between 2000 and 2011. The total number of DSTs performed during this 11-year period was 2 038 and accounted for 2.6% (2 038/78 639) of all the retreatment cases notified. The total number of diagnosed MDR-TB cases for this period was 446, of which 56.3% (251/446) were male and 41.7% (186/446) female. Only one child was found to have MDR-TB. Poly-drug resistance accounted for 18.9% (172/911) of the DR-TB cases and 8.4% of the total DSTs. 8.8% (80/911) of the DR-TB cases showed either rifampicin mono- or poly-resistance other than MDR-TB. No XDR-TB was reported. There were no data available on DR-TB and HIV co-infection. Only 65 MDR-TB patients were notified and put on second-line treatment according to WHO guidelines. Multidrug-resistant tuberculosis may be an emerging challenge in Zambia. There is a need to invest in improving the capacity of the TB programme to detect and manage MDR-TB.
    Tropical Medicine & International Health 09/2013; 18(11). DOI:10.1111/tmi.12183 · 2.33 Impact Factor
  • Source
    • "To this death toll the burden of economic losses (job losses, social segregation, and supervision of special programs for treatment) add up to make tuberculosis a still undefeated global public health enemy. There are few therapeutic options for tuberculosis treatment and clinical strains resistant to one or several of the anti-tubercular drugs have been described [2]–[4]. In order to improve existing drugs or to develop new ones, an understanding of mycobacterial physiology and pathogenesis mechanisms is urgently needed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mycobacteriophages have been essential in the development of mycobacterial genetics through their use in the construction of tools for genetic manipulation. Due to the simplicity of their isolation and variety of exploitable molecular features, we searched for and isolated 18 novel mycobacteriophages from environmental samples collected from several geographic locations. Characterization of these phages did not differ from most of the previously described ones in the predominant physical features (virion size in the 100-400 nm, genome size in the 50-70 kbp, morphological features compatible with those corresponding to the Siphoviridae family), however novel characteristics for propagation were noticed. Although all the mycobacteriophages propagated at 30°C, eight of them failed to propagate at 37°C. Since some of our phages yielded pinpoint plaques, we improved plaque detection by including sub-inhibitory concentrations of isoniazid or ampicillin-sulbactam in the culture medium. Thus, searches for novel mycobacteriophages at low temperature and in the presence of these drugs would allow for the isolation of novel members that would otherwise not be detected. Importantly, while eight phages lysogenized , four of them were also capable of lysogenizing . Analysis of the complete genome sequence obtained for twelve mycobacteriophages (the remaining six rendered partial genomic sequences) allowed for the identification of a new singleton. Surprisingly, sequence analysis revealed the presence of A or A/B genes in 7/18 phages including four that behaved as temperate in . In summary, we report here the isolation and preliminary characterization of mycobacteriophages that bring new information to the field.
    PLoS ONE 02/2013; 8(2):e56384. DOI:10.1371/journal.pone.0056384 · 3.23 Impact Factor
Show more